无创呼吸策略对急性低氧性呼吸衰竭合并COVID-19患者插管或死亡率的影响:RECOVERY-RS随机临床试验
RECOVERY-RS为平行组适应性随机临床试验,纳入1273例COVID-19相关急性低氧性呼吸衰竭住院成人,比较持续气道正压(CPAP)、经鼻高流量氧疗(HFNO)与常规氧疗。30天内气管插管或死亡复合结局:CPAP组36.3% vs 常规氧疗组44.4%,绝对差异-8%(95%CI -15%至-1%,P=0.03);HFNO组44.3% vs 常规氧疗组45.1%,绝对差异-1%(95%CI -8%至6%,P=0.83)。
要点
- CPAP较常规氧疗显著降低30天内气管插管或死亡复合结局(绝对差异-8%,95%CI -15%至-1%)。
- HFNO与常规氧疗相比,30天内气管插管或死亡无显著差异(绝对差异-1%,95%CI -8%至6%)。
- 不良事件发生率:CPAP组34.2%、HFNO组20.6%、常规氧疗组13.9%。
核心结论
- 在COVID-19所致急性低氧性呼吸衰竭患者中,初始CPAP策略较常规氧疗显著降低气管插管或死亡风险,而初始HFNO策略与常规氧疗相比无显著差异。
- 该研究针对HFNO与常规氧疗的比较可能把握度不足,解读结果时应考虑早期终止和组间交叉。
研究设计与样本
- 平行组、适应性随机临床试验,于2020年4月6日至2021年5月3日在英国和泽西的48家急性护理医院开展,最终随访于2021年6月20日。
- 纳入1273例COVID-19相关急性低氧性呼吸衰竭住院成人,随机分为CPAP组(n=380)、HFNO组(n=418)和常规氧疗组(n=475)。
- 因英国COVID-19病例数下降及资助招募期结束,试验提前终止;1260例患者有主要结局数据。
- 患者平均年龄57.4岁(95%CI 56.7至58.1),66%为男性,65%为白人。
主要发现
- 30天内气管插管或死亡复合结局:CPAP组36.3%(137/377)vs 常规氧疗组44.4%(158/356),绝对差异-8%(95%CI -15%至-1%,P=0.03)。
- 30天内气管插管或死亡复合结局:HFNO组44.3%(184/415)vs 常规氧疗组45.1%(166/368),绝对差异-1%(95%CI -8%至6%,P=0.83)。
- 干预间交叉发生率为17.1%,其中CPAP组15.3%、HFNO组11.5%、常规氧疗组23.6%。
- 不良事件发生率:CPAP组34.2%(130/380)、HFNO组20.6%(86/418)、常规氧疗组13.9%(66/475)。
局限性
- 试验因英国COVID-19病例数下降及资助招募期结束而提前终止。
- 该研究针对HFNO与常规氧疗的比较可能把握度不足。
- 解读结果时应考虑早期研究终止和组间交叉。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Continuous positive airway pressure (CPAP) and high-flow nasal oxygen (HFNO) have been recommended for acute hypoxemic respiratory failure in patients with COVID-19. Uncertainty exists regarding the effectiveness and safety of these noninvasive respiratory strategies. OBJECTIVE: To determine whether either CPAP or HFNO, compared with conventional oxygen therapy, improves clinical outcomes in hospitalized patients with COVID-19-related acute hypoxemic respiratory failure. DESIGN, SETTING, AND PARTICIPANTS: A parallel group, adaptive, randomized clinical trial of 1273 hospitalized adults with COVID-19-related acute hypoxemic respiratory failure. The trial was conducted between April 6, 2020, and May 3, 2021, across 48 acute care hospitals in the UK and Jersey. Final follow-up occurred on June 20, 2021. INTERVENTIONS: Adult patients were randomized to receive CPAP (n = 380), HFNO (n = 418), or conventional oxygen therapy (n = 475). MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of tracheal intubation or mortality within 30 days. RESULTS: The trial was stopped prematurely due to declining COVID-19 case numbers in the UK and the end of the funded recruitment period. Of the 1273 randomized patients (mean age, 57.4 [95% CI, 56.7 to 58.1] years; 66% male; 65% White race), primary outcome data were available for 1260. Crossover between interventions occurred in 17.1% of participants (15.3% in the CPAP group, 11.5% in the HFNO group, and 23.6% in the conventional oxygen therapy group). The requirement for tracheal intubation or mortality within 30 days was significantly lower with CPAP (36.3%; 137 of 377 participants) vs conventional oxygen therapy (44.4%; 158 of 356 participants) (absolute difference, -8% [95% CI, -15% to -1%], P = .03), but was not significantly different with HFNO (44.3%; 184 of 415 participants) vs conventional oxygen therapy (45.1%; 166 of 368 participants) (absolute difference, -1% [95% CI, -8% to 6%], P = .83). Adverse events occurred in 34.2% (130/380) of participants in the CPAP group, 20.6% (86/418) in the HFNO group, and 13.9% (66/475) in the conventional oxygen therapy group. CONCLUSIONS AND RELEVANCE: Among patients with acute hypoxemic respiratory failure due to COVID-19, an initial strategy of CPAP significantly reduced the risk of tracheal intubation or mortality compared with conventional oxygen therapy, but there was no significant difference between an initial strategy of HFNO compared with conventional oxygen therapy. The study may have been underpowered for the comparison of HFNO vs conventional oxygen therapy, and early study termination and crossover among the groups should be considered when interpreting the findings. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN16912075.
引用
- Perkins GD, Ji C, Connolly BA, et al. Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial. JAMA. 2022. PMID: 35072713. doi:10.1001/jama.2022.0028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。